Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARWR Arrowhead Pharmaceuticals	$15.71 +2.4%	$13.30	$9.57 ▼ $30.41	$2.17B	0.89	1.48 million shs	1.82 million shs
GMTX Gemini Therapeutics	$48.09 +2.1%	$46.22	$1.16 ▼ $14.10	$2.08B	-0.12	189,291 shs	442,392 shs
SBTX Silverback Therapeutics	$13.60 +11.5%	$13.31	$2.80 ▼ $8.97	$490.39M	0.6	337,931 shs	2.21 million shs
TVTX Travere Therapeutics	$16.80 -20.6%	$18.25	$6.01 ▼ $25.29	$1.49B	0.88	1.56 million shs	5.97 million shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARWR Arrowhead Pharmaceuticals	0.00%	+20.75%	+39.77%	-21.25%	-37.26%
GMTX Gemini Therapeutics	+2.12%	+8.70%	+17.29%	-11.11%	+51.04%
SBTX Silverback Therapeutics	+11.52%	+1.19%	-8.60%	+13.14%	+53.15%
TVTX Travere Therapeutics	0.00%	-16.08%	+12.60%	-26.67%	+147.06%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARWR Arrowhead Pharmaceuticals	3.341 of 5 stars	3.3	1.0	0.0	3.4	2.1	2.5	0.0
GMTX Gemini Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SBTX Silverback Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TVTX Travere Therapeutics	2.9678 of 5 stars	4.4	2.0	0.0	0.0	3.0	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARWR Arrowhead Pharmaceuticals	2.67	Moderate Buy	$42.13	168.14% Upside
GMTX Gemini Therapeutics	0.00	N/A	N/A	N/A
SBTX Silverback Therapeutics	0.00	N/A	N/A	N/A
TVTX Travere Therapeutics	2.87	Moderate Buy	$31.79	89.20% Upside

Current Analyst Ratings Breakdown

Latest SBTX, ARWR, GMTX, and TVTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/16/2025	TVTX Travere Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$30.00 ➝ $30.00
5/13/2025	ARWR Arrowhead Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$21.00 ➝ $17.00
5/13/2025	ARWR Arrowhead Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$60.00 ➝ $60.00
5/2/2025	TVTX Travere Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$30.00 ➝ $30.00
5/2/2025	TVTX Travere Therapeutics	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Hold ➝ Hold	$22.00 ➝ $23.00
4/23/2025	TVTX Travere Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight
4/14/2025	TVTX Travere Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$47.00 ➝ $47.00
4/11/2025	TVTX Travere Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
4/10/2025	TVTX Travere Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$45.00 ➝ $47.00
4/3/2025	TVTX Travere Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight
4/1/2025	TVTX Travere Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$29.00 ➝ $31.00

(Data available from 5/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARWR Arrowhead Pharmaceuticals	$545.21M	3.98	N/A	N/A	$1.54 per share	10.20
GMTX Gemini Therapeutics	N/A	N/A	N/A	N/A	$2.89 per share	N/A
SBTX Silverback Therapeutics	N/A	N/A	N/A	N/A	$7.41 per share	N/A
TVTX Travere Therapeutics	$273.53M	5.45	N/A	N/A	$2.67 per share	6.29

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARWR Arrowhead Pharmaceuticals	-$599.49M	-$1.40	N/A	N/A	N/A	N/A	-236.60%	-64.09%	N/A
GMTX Gemini Therapeutics	-$71.87M	-$1.00	N/A	N/A	N/A	N/A	-38.78%	-35.88%	N/A
SBTX Silverback Therapeutics	-$89.48M	-$2.42	N/A	∞	N/A	N/A	-29.62%	-28.20%	N/A
TVTX Travere Therapeutics	-$111.40M	-$2.81	N/A	N/A	N/A	-137.90%	-1,636.87%	-55.95%	N/A

Latest SBTX, ARWR, GMTX, and TVTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/12/2025	Q2 2025	ARWR Arrowhead Pharmaceuticals	-$0.06	$2.75	+$2.81	$2.75	$116.27 million	$542.71 million
5/1/2025	Q1 2025	TVTX Travere Therapeutics	-$0.55	-$0.47	+$0.08	-$0.47	$77.44 million	$81.73 million
2/20/2025	Q4 2024	TVTX Travere Therapeutics	-$0.58	-$0.73	-$0.15	-$0.73	$72.38 million	$74.79 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARWR Arrowhead Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
GMTX Gemini Therapeutics	N/A	N/A	N/A	N/A	N/A
SBTX Silverback Therapeutics	N/A	N/A	N/A	N/A	N/A
TVTX Travere Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARWR Arrowhead Pharmaceuticals	7.27	6.09	6.09
GMTX Gemini Therapeutics	N/A	71.49	71.49
SBTX Silverback Therapeutics	N/A	67.87	67.87
TVTX Travere Therapeutics	24.96	1.71	1.68

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARWR Arrowhead Pharmaceuticals	62.61%
GMTX Gemini Therapeutics	75.42%
SBTX Silverback Therapeutics	74.89%
TVTX Travere Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
ARWR Arrowhead Pharmaceuticals	4.30%
GMTX Gemini Therapeutics	12.90%
SBTX Silverback Therapeutics	34.40%
TVTX Travere Therapeutics	4.19%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARWR Arrowhead Pharmaceuticals	400	138.10 million	120.68 million	Optionable
GMTX Gemini Therapeutics	30	43.33 million	37.74 million	Not Optionable
SBTX Silverback Therapeutics	83	36.06 million	23.65 million	Not Optionable
TVTX Travere Therapeutics	460	88.81 million	75.12 million	Optionable

SBTX, ARWR, GMTX, and TVTX Headlines

Recent News About These Companies

Northern Trust Corp Has $13.14 Million Position in Travere Therapeutics, Inc. (NASDAQ:TVTX)

May 18 at 3:22 AM | marketbeat.com

Travere Therapeutics stock falls on FDA review setback

May 16 at 5:12 PM | in.investing.com

Travere flops as FDA accepts Filspari sNDA but plans AdCom

May 16 at 5:12 PM | thepharmaletter.com

Travere Therapeutics, Inc. (NASDAQ:TVTX) Shares Purchased by Parkman Healthcare Partners LLC

May 16 at 8:12 AM | marketbeat.com

Travere Therapeutics Announces FDA Acceptance of sNDA for FILSPARI® (sparsentan) in FSGS

May 15 at 4:05 PM | businesswire.com

Algert Global LLC Invests $282,000 in Travere Therapeutics, Inc. (NASDAQ:TVTX)

May 15 at 3:53 AM | marketbeat.com

Travere Therapeutics, Inc. (NASDAQ:TVTX) Stock Position Reduced by Price T Rowe Associates Inc. MD

May 15 at 3:27 AM | marketbeat.com

Integral Health Asset Management LLC Buys New Position in Travere Therapeutics, Inc. (NASDAQ:TVTX)

May 14, 2025 | marketbeat.com

J. Goldman & Co LP Makes New Investment in Travere Therapeutics, Inc. (NASDAQ:TVTX)

May 14, 2025 | marketbeat.com

Jacobs Levy Equity Management Inc. Has $37.88 Million Stock Position in Travere Therapeutics, Inc. (NASDAQ:TVTX)

May 14, 2025 | marketbeat.com

Schonfeld Strategic Advisors LLC Sells 152,820 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX)

May 13, 2025 | marketbeat.com

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 12, 2025 | businesswire.com

Brevan Howard Capital Management LP Sells 30,742 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX)

May 12, 2025 | marketbeat.com

1,209,810 Shares in Travere Therapeutics, Inc. (NASDAQ:TVTX) Purchased by BNP Paribas Financial Markets

May 12, 2025 | marketbeat.com

Driehaus Capital Management LLC Has $38.64 Million Stock Holdings in Travere Therapeutics, Inc. (NASDAQ:TVTX)

May 11, 2025 | marketbeat.com

Travere Therapeutics, Inc. (NASDAQ:TVTX) Shares Acquired by Crestline Management LP

May 10, 2025 | marketbeat.com

Travere Therapeutics, Inc. (NASDAQ:TVTX) Stake Boosted by AQR Capital Management LLC

May 10, 2025 | marketbeat.com

Hsbc Holdings PLC Has $487,000 Stock Holdings in Travere Therapeutics, Inc. (NASDAQ:TVTX)

May 9, 2025 | marketbeat.com

Travere Therapeutics, Inc. (NASDAQ:TVTX) Insider Sells $37,279.55 in Stock

May 8, 2025 | marketbeat.com

Travere Therapeutics, Inc. (NASDAQ:TVTX) CFO Sells $37,553.20 in Stock

May 8, 2025 | marketbeat.com

Travere Therapeutics, Inc. (NASDAQ:TVTX) CEO Sells $398,350.20 in Stock

May 8, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SBTX, ARWR, GMTX, and TVTX Company Descriptions

Arrowhead Pharmaceuticals NASDAQ:ARWR

$15.71 +0.37 (+2.41%)

Closing price 05/16/2025 04:00 PM Eastern

Extended Trading

$15.49 -0.22 (-1.40%)

As of 05/16/2025 07:44 PM Eastern

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.

Gemini Therapeutics NASDAQ:GMTX

$48.09 +1.00 (+2.12%)

As of 05/16/2025

Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.

Silverback Therapeutics NASDAQ:SBTX

$13.60 +1.41 (+11.52%)

As of 05/16/2025

Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

Travere Therapeutics NASDAQ:TVTX

$16.80 -4.35 (-20.57%)

Closing price 05/16/2025 04:00 PM Eastern

Extended Trading

$16.87 +0.07 (+0.41%)

As of 05/16/2025 07:20 PM Eastern

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. The company's clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time